DUBLIN – Affibody AB is getting $10 million up front and up to $215.5 million in regulatory and sales milestones from a licensing deal with Inmagene Biopharmaceuticals Co. Ltd., in which the latter firm gains commercial rights to its interleukin-17 inhibitor ABY-035 in China, Hong Kong, Taiwan, Macau and South Korea. Read More

HONG KONG – South Korea’s Daewon Pharmaceutical Co. Ltd. has launched Terrosa, a teriparatide biosimilar for the treatment of osteoporosis, acquired from Hungarian firm Richter-Helm Biotec GmbH & Co KG. It’s the first biosimilar launch for the company. Read More

BEIJING – Legend Biotech Corp., headquartered in Somerset, N.J., filed with the U.S. SEC last week plans to raise up to $100 million to advance its BCMA-targeting CAR T candidate, LCAR-B38M, by listing on Nasdaq. Legend confidentially submitted a draft registration statement to the regulators in March. Read More

HONG KONG – France’s Sanofi SA has informed Hanmi Pharmaceuticals Co. Ltd. of its intention to return all the rights to efpeglenatide, the South Korean company’s diabetes drug candidate. Read More

HONG KONG –Shanghai-based Zai Lab Ltd. has won an approval for the first innovative treatment for glioblastoma approved by China in more than 15 years, with the National Medical Products Administration’s nod for Optune in combination with temozolomide for use in patients with newly diagnosed glioblastoma. Read More

BEIJING – Shandong, China-based Luoxin Pharmaceuticals Group Stock Co. Ltd. said its PIK3α inhibitor, LX-086, has been approved by China’s National Medical Products Administration (NMPA) to enter clinical trials for advanced solid tumors. Read More

PERTH, Australia – Australian stem cell company Mesoblast Ltd. completed a capital raising of AU$138 million (US$90 million) to scale up manufacturing of its allogeneic cell therapy, remestemcel-L, to treat COVID-19 acute respiratory distress syndrome (ARDS). Read More

HONG KONG – Blockchain technology usually is associated with digital currencies. However, it’s now emerging as an important platform for COVID-19 management. It’s been a focus in China, where a top-down approach is key to driving sectors and technology. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Acer, Akers, Avacta, Bonus Biogroup, Cansino, Cellect, Cipla, Citius, Cmab, Creoptix, Curevac, Cytoagents, E-therapeutics, Exvastat, Gilead, Glaxosmithkline, Gryt, Iksuda, Immunovative, Jubilant, Legend Biotech, Legochem, Lengo, Luye, Manhattan Biosolutions, Medicago, Mercaptor Discoveries, Mirror, Moksha8, Mylan, Mymetics, Nanoviricides, Nascent, Novellus, Orgenesis, Patrys, Pluristem, Predictive Oncology, Premas, Primary Peptides, Promis, Qurebio, Recursion, Simcere, Sorrento, Syntekabio, Takeda, Teva, Transgene, Vir, Viralclear, Vsy, Wize, Wuxi, Yumab. Read More

Biopharmas in Asia-Pacific raising money in public or private financings, including: Abivax, Apeiron, Greenlight, Hemogenyx, Modulus Discovery, Peptidream, Travecta. Read More

The latest global regulatory news, changes and updates affecting biopharma, including: Cybersecurity and Infrastructure Security Agency, EMA, European Commission, FBI, FDA, Glaxosmithkline, National Institute for Health and Care Excellence, NIH, U.K. National Cyber Security Agency, U.S. Department of Justice. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Abivax, Astellas, Bone, Glenmark, I-Mab, JHL, Kaleido, Moderna, Neurorx, Oryzon Genomics, Relief, Roivant Sciences, Samsung Bioepis, Taiwan Liposome, Zai Lab. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Abivax, Aim Immunotech, Akebia, Algernon, Ascletis, Astrazeneca, Biosig Technologies, Can-Fite, Carsgen, Cytodyn, Daiichi Sankyo, Enzychem Lifesciences, Immunic, Kancera, Leading Biosciences, Moderna, Nantkwest, Novocure, Pharmazz, Restem, Scimount, Seattle Genetics, Takeda, Teva, Vistagen, Zai Lab. Read More

New and updated preclinical and clinical data related to Asia to be presented at the American Society of Clinical Oncology’s annual meeting – May 29-31. Read More